No Picture
News

New Cell-Based Technology by Cytonus Aims to Revolutionize the Fight against Cancer and Inflammatory Diseases

SAN DIEGO–(BUSINESS WIRE)–Cytonus Therapeutics Inc. announced today that it has developed Cargocytes? a first-of-its-kind, controllable, cell-based platform technology for delivery of biologics. Cargocytes are engineered allogenic cell lines that can… […]

No Picture
News

Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting

SAN DIEGO–(BUSINESS WIRE)–Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from studies of its lead antifungal rezafungin will be presented at the … […]

No Picture
News

Richard Pascoe takes the helm at Histogen; Lonza COO steps up at CEO Richard Ridinger retires

Richard Pascoe
? Having handed off troubled microcap biotech Apricus Biosciences to Seelos Therapeutics via a merger, Richard Pascoe is moving on to his next CEO (and chairman) gig at Histogen. The regenerative medicine developer is anticipating data f… […]

No Picture
News

Technological Breakthroughs in Data Center Connectivity, 5G and IoT, Next-Generation Optical Access and Open Networking Innovation Drive OFC 2019 Conference Program and Exhibits

SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/OSA?src=hash" target="_blank"gt;#OSAlt;/agt;–OFC 2019 returns to San Diego, California to set the stage as the single-most important annual event in optical communi… […]

No Picture
News

Unfazed by Brexit blues, UK biotech trade group celebrates boisterous year of venture dollars with record ?1.1B total

A record year of venture investing has floated UK?s biotech boat, with the money flow in 2018 gushing over the ?1 billion mark for the first time.
A total of ?1.1 billion was raised thanks to a boom in late-stage financings, according to the latest rep… […]

No Picture
News

Imbruvica regimen wins FDA approval as first non-chemotherapy treatment for untreated patients with common form of leukemia

In the 10th approval since its 2013 launch, J&J?s cancer drug Imbruvica has secured the FDA nod in combination with Roche?s?obinutuzumab in adults with the most common form of leukemia?? marking the first non-chemotherapy regimen for treatment-na?v… […]